Mosaic ImmunoEngineering Inc.
CPMV evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CPMV—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CPMV
Mosaic ImmunoEngineering Inc. is a preclinical-stage biotechnology company focused on developing cancer therapeutics, currently with no revenue and minimal cash reserves, facing significant going-concern risks.
Key risk: Going concern risk
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Mosaic ImmunoEngineering Inc. is a preclinical-stage biotechnology company focused on developing cancer therapeutics, currently with no revenue and minimal cash reserves, facing significant going-concern risks.
- Cash and cash equivalents were less than $1,000 as of June 30, 2026 [sec_mda · as of 2026-08-14].
- Net loss was -$0.2M for the period as of June 30, 2026 [sec].
- Shareholders' equity was -$7.5M as of June 30, 2026 [sec].
- Total debt was $1.5M as of June 30, 2026 [sec].
- The company has not advanced any product candidate from preclinical development into clinical development [sec_mda · as of 2025-04-15].
What works
- The company has a license agreement with Case Western Reserve University for potential cancer therapeutics [sec_mda · as of 2024-04-15].
- The company continues to seek new product candidates and technologies to expand its pipeline [sec_mda · as of 2025-04-15].
What to weigh
- Cash and cash equivalents were less than $1,000 as of June 30, 2026, and the company expects it will not satisfy operational requirements for twelve months [sec_mda · as of 2026-08-14].
- The company has been unable to raise sufficient capital to advance any product candidate into clinical development [sec_mda · as of 2025-04-15].
- The company has a history of operating losses and expects to continue incurring significant losses [sec_mda · as of 2026-04-15].
- If unable to raise additional capital, the company may be forced to cease operations [sec_mda · as of 2026-04-15].
From the filings
Quoted directly from source documents.
The company's cash position is critically low.
“As of June 30, 2026, we had cash and cash equivalents of less than $1,000.”
SEC MD&A · August 14, 2026
The company may not have sufficient capital to continue operations.
“Our ability to continue our operations is highly dependent on our ability to raise capital to fund future operations.”
SEC MD&A · August 14, 2026
The company has not advanced any product candidate to clinical trials.
“Since the closing date of the Reverse Merger, we have been unable to raise sufficient capital to advance any product candidate from preclinical development into clinical development.”
SEC MD&A · April 15, 2025
The company faces a going concern risk.
“If we are unable to raise additional capital, we may be forced to cease our operations altogether.”
SEC MD&A · April 15, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Cash <$1,000 as of June 30, 2026; may not meet obligations for 12 months [sec_mda · as of 2026-08-14].
- No clinical-stage pipeline — No product candidate has advanced beyond preclinical development [sec_mda · as of 2025-04-15].
- Dependence on external financing — Unable to raise sufficient capital; future financing uncertain [sec_mda · as of 2025-04-15].
- History of losses — Net loss of -$0.2M as of June 30, 2026; expects continued losses [sec].
What to watch
- Ability to raise additional capital to fund operations and avoid cessation [sec_mda · as of 2026-08-14].
- Progress in identifying and licensing new product candidates [sec_mda · as of 2026-04-15].
- Any updates on the license agreement with Case Western Reserve University [sec_mda · as of 2024-04-15].
Sources: SEC MD&A · Generated August 21, 2026 · How we verify sources →
Run Mosaic ImmunoEngineering Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Mosaic ImmunoEngineering Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
65.3 months
OCF -$46 · Net income -$177K
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Frequently asked questions
What is the AI investment thesis for Mosaic ImmunoEngineering Inc.?
Mosaic ImmunoEngineering Inc. is a preclinical-stage biotechnology company focused on developing cancer therapeutics, currently with no revenue and minimal cash reserves, facing significant going-concern risks.
Who is the CEO of Mosaic ImmunoEngineering Inc.?
Mr. Steven W. King is the chief executive officer of Mosaic ImmunoEngineering Inc. (CPMV).
Where is Mosaic ImmunoEngineering Inc. headquartered?
Mosaic ImmunoEngineering Inc. (CPMV) is headquartered in Huntington Beach, CA, United States.
What therapeutic areas does Mosaic ImmunoEngineering Inc. focus on?
Mosaic ImmunoEngineering Inc. develops therapies across Oncology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.